Shin Poong Enhances Shareholder Value via Share Cancellation and Strategic Alliance with Hyundai Pharm
Share cancellation: Cancelled 566,468 common and 208,770 preferred shares via retained earnings (completed March 25, 2026), reducing total shares outstanding.
Strategic alliance with Hyundai Pharm: Exchanged 2,437,310 treasury shares for Hyundai Pharm's treasury shares to enhance business synergy and R&D partnership.
Operating loss narrowed: Consolidated operating loss of 363 million KRW in Q1 2026 (vs 1,763 million loss in Q1 2025), sales of 54.53 billion KRW (down 1.6% YoY from 55.41 billion).
Net loss attributable to controlling interest: 8.08 billion KRW loss (compared to net income of 114 million in Q1 2025? Data inconsistency noted).
Improved financial structure: Net debt ratio 0.57% (year-end 2025: 2.71%), total borrowings 53.81 billion, cash equivalents 52.15 billion.
Exchangeable bonds issued: 11.5 billion won zero-coupon private exchangeable bonds (issued Dec 3, 2025, maturity Dec 3, 2030), exchange price 16,193 won, underlying treasury shares 710,183.
R&D expenditure: 6.51 billion won (11.95% of sales), ongoing key pipelines (SP-8203 phase 3 for stroke, SP5M002 phase 3 for osteoarthritis).
New business: Added animal medicine and medical device business purposes to articles of incorporation (Mar 30, 2026), currently in feasibility study.
Contingent liabilities & litigation: Supreme court ruled company not liable in former executives' embezzlement/breach of trust case (May 8, 2025); further losses unlikely.